Skip to content

Earnings call

Advanced Enzyme Technologies Q2 FY25 earnings call: Advanced Enzyme Technologies Limited's business does not operate on a PO basis, and the value of POs at any given time is not more than 10, 12 Crores

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Business does not operate on a PO basis, and the value of POs at any given time is not more than 10, 12 Crores. The company does not anticipate growth in domestic sales for financial year '25. EBITDA was INR424 million, down 17% year-on-year and sequentially, in the quarter ended 30th September, 2024. Requests to feature its formulated ingredient brand names on finished consumer products had risen 58% compared to last year at the halfway point of the year. The company introduced 2 new solutions in the last quarter and is collaborating with customers to finalize the optics.

The numbers management gave

Results

  • EBITDA was INR424 million, down 17% year-on-year and sequentially, in the quarter ended 30th September, 2024.
    Show source
    Our EBITDA stood at INR424 million, degrew by 17% on a year-on-year basis as well as on a sequential basis.
  • Bottom line declined 5% year-on-year and sequentially in the quarter ended 30th September, 2024.
    Show source
    We have witnessed degrowth of 5% in the bottom line on a year-on-year basis and on a sequential basis.
  • EBITDA margin was 29% and PAT margin was 23% in the quarter ended 30th September, 2024.
    Show source
    EBITDA margin stood at 29% and PAT margin stood at 23% during the quarter 2.
  • The company had a higher revenue reversal of INR83 million during the quarter ended 30th September, 2024, compared to the previous quarter, because revenue recognition criteria were not met as per the accounting standard; revenue and margin from these sales were deferred to quarter 3.
    Show source
    During the quarter, the company had a higher revenue reversal of INR83 million compared to the previous quarter since revenue recognition criteria was not made as per the accounting standard.
  • Human Nutrition segment contributed 68% of revenue and declined during the quarter ended 30th September, 2024.
    Show source
    The Human Nutrition segment declined during the quarter and contributed 68% in the revenue pie.
  • Animal Nutrition business contributed 12% of revenue in quarter 2.
    Show source
    It degrew by 6% on a year-on-year basis and 2% on a sequential basis.
Show 10 more statements

Results

  • Animal Nutrition segment grew 5% year-on-year and 6% sequentially in the quarter ended 30th September, 2024.
    Show source
    This segment grew by 5% on a year-on-year basis, while it grew by 6% on a sequential basis.
  • Food business declined 42% and its Non-Food business grew 24% year-on-year in the quarter ended 30th September, 2024; the Food business mainly comes from export markets and sales reversals impacted it.
    Show source
    The Food business degrew by 42%, while Non-Food business reported a growth of 24% on a year-on-year basis.
  • Specialized Manufacturing business contributed 8% and grew 17% year-on-year and 9% sequentially in the quarter ended 30th September, 2024.
    Show source
    The Specialized Manufacturing business contributed 8% and grew by 17% on a year-on-year basis and 9% on a sequential basis.
  • USA company reported international business revenue of INR403 million in Q2 of last year, INR494 million in Q1 of this year, and INR532 million in Q2 of current year.
    Show source
    And Q2 of current year, it stood at INR532 million.
  • The company spent about INR72 million on R&D during Q2, compared to INR62 million last year.
    Show source
    So I think our R&D expenditure, as we generally mentioned about our spending on R&D during Q2, we have spent about INR72 million as compared to INR62 million last year.
  • Capex was about INR13 million in Q2, compared to INR2 million last year.
    Show source
    And our capex is about INR13 million as compared to INR2 million last year.
  • Sales were down about 1% and EBITDA was down 2% on a year-to-date basis; with incremental sales, EBITDA increases by at least 2x to 2.5x or 3x.
    Show source
    On YTD basis, if you really see the sale number is down, say, about 1% but EBITDA is down by 2%.
  • The company had an impact of about INR1.5 crores in the quarter ended 30th September, 2024, particularly because of the higher freight cost.
    Show source
    We have, an impact, of about INR1.5 crores in this quarter, particularly because of the freight cost.
  • Export sales slowdown led to a decline in international sales, excluding the US, partly because of sales reversal.
    Show source
    A slowdown in our export sales lead to decline in international sales, excluding the US, and some of this is because of the sales reversal as well.
  • Probiotic and Nutrition business performed well in international markets. Replaced by a later filing.
    Show source
    In the international markets, Probiotic and Nutrition business performed well.

What it expects ahead

What management expects

  • The company does not anticipate growth in domestic sales for financial year '25.
    Show source
    As projected at the start of the fisc al 2025, we do not anticipate growth in domestic sales for this year.
  • US sales increased by 24% on a year-to-date basis, and its US business is expected to perform stronger in financial year '25.
    Show source
    However, our US business is expected to perform stronger in financial year '25, with US sales having already increased by 24% on a year - to-date basis.
  • The company expects growth in financial year '25 to be in the single-digit range.
    Show source
    Consequently, the anticipated growth for financial year '25 is expected to be in the single-digit range.
  • The company expects about INR115 to INR120 Crores for serra for the year.
    Show source
    Mukund Kabra: We will be expecting about INR115 to INR120 Crores for the year.
  • The company said it did not expect any customer loss in European business this year, except for a small $1 million sale realized last year that would not recur because the customer changed the process in other areas; it expects European business to pick up.
    Show source
    Yes, there is a small one, which was like $1 million, which we realized last year, which we are knowing that this year will not be coming up because of some other reasons because the -- they changed the process in other areas.
  • The company expects its EBITDA margin to be in the range of 30% to 33% as revenue increases.
    Show source
    It will be in the range of 30% to 33%.
Show 5 more statements

What management expects

  • The company expects its EBITDA margin to improve as the second half of this fiscal year progresses; the margin was subdued mainly because of lower top line.
    Show source
    Our EBITDA margin is subdued majorly due to the lower top line, but we expect this to improve as we progress into the second half of this fiscal year.
  • The company expects single-digit growth for the year, revising its earlier expectation of double-digit growth because sales expected from other areas are slightly delayed and it probably will not have growth on the Indian front; it expects the next half to be better but may not achieve double-digit growth.
    Show source
    Mukund Kabra: So Harini, let me correct you, like earlier, we were expecting a double-digit growth, but this time, we feel that we will have a single-digit growth, and that is what I've made it clear in my initial remarks.
  • Mukund Kabra does not expect Advanced Enzyme Technologies Limited to make any acquisition in the US in the next one years.
    Show source
    Mukund Kabra: No. In next one years, I don't expect any acquisition at least in the US, particularly.
  • The company has a purchase order for Evoxx sales that is spread over a whole year and expects the next half year to be better for the US, with probably higher sales than the low last year, particularly in the US.
    Show source
    We do have a PO of that, which is pan out for a whole year, and that is where we expect that the next half year will be the better for the US.

Orders

  • Business does not operate on a PO basis, and the value of POs at any given time is not more than 10, 12 Crores.
    Show source
    The number of POs at any given time is not more than 10, 12 Crores.

What it is building and selling

Demand and pricing

  • Requests to feature its formulated ingredient brand names on finished consumer products had risen 58% compared to last year at the halfway point of the year.
    Show source
    At the halfway point of the year, request to feature our formulated ingredient brand names on finished consumer products have already risen by 58% compared to last year.
  • The company observed increasing demand for its inventive probiotics in the US market despite new competitors entering its sector in recent years.
    Show source
    Despite the influx of new competitors in our sector in recent years, we continue to observe increasing demand for our inventive probiotics in the US market.
  • The company said its US customer faces a lack of familiarity with enzyme and probiotic testing, compounded by a fragmented and under-educated market for third-party testing services; this can waste resources as customers struggle with basic quality control requirements and places pressure on sales.
    Show source
    A significant challenge for our US customer is the lack of Page 3 of 18 Advanced enzymes Advanced Enzyme Technologies Limited ' IVtiL’ful.X/YMllbLilt‘ November 13, 2024 familiarity with enzyme and probiotic testing, compounded by a fragmented and under-educated market for third-party testing services.
  • The company said there was competition in its anti-inflammatory market. Replaced by a later filing.
    Show source
    As we mentioned in our earlier calls as well, there is certain competition in our anti -inflammatory market.

Segments

  • The company introduced 2 new solutions in the last quarter and is collaborating with customers to finalize the optics.
    Show source
    In the last quarter, we introduced 2 new solutions and are collaborating with customers to finalize the optics.

Risks, rules and outside factors

Outside factors

  • The company said freight costs were on the higher side and other issues were affecting some credits and other areas, and it was working to resolve those problems.
    Show source
    At the same time, there are certain issues, some of the issues are coming with the freight and all of those areas, the freight cost is also on a higher side.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Harini Dedhia: Right. My question was on serratiopeptidase. We had called it out specifically as a reason for degrowth in India in Q1. And you had said that there's some inventory that's not being run down at the customer end, which is taking longer than expected. Is this still the problem in India, or is the problem a little more structural in nature or is it a temporary issue? Just wanted to understand that.

    Answer, mukund kabra

    Mukund Kabra: Harini, serra sales is down but it is not down to the extent what these numbers are showing. Last year, the serra sale was there in the first half and it was down into the next half. So on an overall basis, if you ask me, it is down somewhere around 7%, 8%. We expect that will be down by 7%, 8% on the volume basis.

  2. Question

    Harini Dedhia: Got it. And so are we expecting then some sort of normalization in the sales in Q3, Q4? Or like in general, in the second half, or this is continue -- the run rate has come off? Page 6 of 18 Advanced enzymes Advanced Enzyme Technologies Limited ' IVtiL’ful.X/YMllbLilt‘ November 13, 2024 Mukund Kabra: So we were already saying that there is going to be some competition, which we do expect in the serra area and this area particularly.

    Answer, mukund kabra

    And that is where we are coming at it, we've forecasted this year as well our sales in this area will be down somewhere around 7% to 8%.

  3. Question

    Harini Dedhia: Okay. And my second question was in the start of the year, we were very clear in our communication and stating that India is unlikely to grow this year. I'm guessing because of serra, predominantly. And then in US, we were confident to grow ahead of the rest of the geographies. And we are still confident of a double-digit growth playing out for the full year. So what has not panned out according to our plan? So is it that India de-growth is steeper than our expectations? Or is it that something has gone up in the rest of the world that is really hurting us?

    Answer, mukund kabra

    Mukund Kabra: So Harini, let me correct you, like earlier, we were expecting a double-digit growth, but this time, we feel that we will have a single-digit growth, and that is what I've made it clear in my initial remarks. We were thinking was some of the sales from the other areas which we are expecting to come out, they are slightly delayed. And that is where we s ee that this year probably on the Indian front probably we will not have any growth, right? And that will impact on our -- and that is where it's difficult for us to get into the double-digit growth here. We do feel that the next half will be better. At the same time, we may not be able to achieve double-digit growth.

  4. Question

    Harini Dedhia: Got it. But even to achieve a single-digit growth number, the next 2 quarters, we will have to do about INR350 crores or right of 170...

    Answer, mukund kabra

    Mukund Kabra: Yes. So if you really look at it, like as Rauka ji explained you, we had some sales reversal, which is already if it wouldn't have been there, it probably would have been flat. And these are the accounting practices -- even though the invoices are there, the material has not reached to the customer. Some of the delays are because of the shipping delays and orders, the other airlines' delays or whatever we can call it. But that is not in our hand. Right? So those sales will be -- those sales will be realized in the next quarter.

  5. Question

    Sandeep Dixit: So does that equation hold even now? So if you are saying that revenue growth for full year '25 will be single digit, will the EBITDA growth still be 2x that?

    Answer, beni rauka

    Beni Prasad Rauka: So if you really look at -- let me answer your question. If you really look at the de-growth. So if the equation if you are talking about, if sales is, say, down by 5% on Q-o-Q, the EBITDA is down by 17%. So that's how you can see the equation in that sense. On YTD basis, if you really see the sale number is down, say, about 1% but EBITDA is down by 2%. So the equation is, in that sense, when you have the incremental sales, your EBITDA always keeps on increasing by at least 2x to 2.5x or 3x. That's how it is.

    Answer, mukund kabra

    Mukund Kabra: So when you have a very high percentage of market share, it's always we are bound to lose some of it. Because whatever you try to do, at some point, some people will come up with the same product, right? So the competition is for the same product and not with the other molecule. So the molecule is still intact.

  6. Question

    Umang Shah: Sure, sir. That is 1 question. Second is, sir, every quarter, you break down the Human Nutrition revenues between India and international. Can you give that number, please?

    Answer, beni rauka

    Beni Prasad Rauka: So Human Nutrition pharma sales has been INR419 million in current quarter as compared to INR593 million in the quarter 2 last year. Our international sales has been INR573 million in the current quarter compared to INR466 million in last year's September quarter.

  7. Question

    Umang Shah: Sure. Rauka ji, what would be the revenue, R&D expenditure for the 6 months as compared to last half?

    Answer, beni rauka

    Beni Prasad Rauka: But I will give you the number. Yes, so in these 6 months, we have spent INR143 million in revenue expenditure in R&D compared to INR121 million in last year's 6 months. Okay. We have already explained capex, right? INR18 million and INR5 million. This year, it was INR18 million. Last year, it was INR5 million.

  8. Question

    And sir, any news on how the new launches are doing in the current year, both in pharma and nutraceutical in US?

    Answer, mukund kabra

    Mukund Kabra: In biocatalyst areas, we have just come out with a couple of solutions, as I mentioned. In the US, there are no new launches. It's the same products but we are focusing more right now.

  9. Question

    Umang Shah: Sure. Okay. And any traction on the launches that you have made last year?

    Answer, mukund kabra

    Mukund Kabra: So those are -- we were talking about on the Pet food. And I think we are talking about the sugar one, right? So those areas are growing, and probably those are the ones which are driving the sales at this point of time. We expect it to grow further as we move on.

  10. Question

    Umang Shah: Sure, sir. And sir, biocatalysis, segment pharma driven. We were thinking that this year would be the year where the segment sales ramped up significantly. Can we expect a positive surprise in the second half?

    Answer, mukund kabra

    Mukund Kabra: We're expecting in third and fourth quarter, but probably what we feel is, which is a little bit delayed. We do have the molecules ready, but to commercialize it and take to the sales on a higher level, probably, this may not happen in this year, but maybe the next year. But yes, the fourth quarter will be a little better than what we had on all the 2 or 3 quarters, what we can say.

    Answer, mukund kabra

    Mukund Kabra: It takes time. Even though I feel 25% growth is a little impossible or a little difficult to do it, not impossible, but difficult to do it. But what we need is more R&D support and more products to come out as we move on. And we are focusing on many of these areas, particularly into the R&D areas. We are trying to increase our R&D capacity. Probably, it will take some more time. Till that time, probably, we will not see the 25% kind of growth, which is a little difficult to achieve.

Show 17 more questions
  1. Question

    Sagar Tanna: Sir, which are the Indian companies who are our competitors, both in India and overseas? And what would be their size?

    Answer, mukund kabra

    Mukund Kabra: So in India, I won't say like there is much of a competition, but a lot of the competition comes from the global players, where their R&Ds are much stronger. And probably, it will take some more time for us to reach to those levels.

  2. Question

    And part of the year, you mentioned that you'll actually grow in a particular range. Now, were you surprised in terms of the difficulties which you are facing now? And how do you think you will end the year at? And what actually changed in the last 7 to 8 weeks?

    Answer, mukund kabra

    Mukund Kabra: What we see is some of the sales which we are expecting from the biocatalyst area to come into the next 1 or 2 quarters, those are going to be deferred, right? From the very beginning, we were anticipating that the Indian sales will be more or less muted this year because we were anticipating the growth to come from the US. For India side, we are expecting the growth to come from the biocatalyst and other areas. Which is deferred, and that is where we feel that double-digit growth is a little difficult, but we will be having single-digit growth at this point of time. That is what we feel. That is what we are communicating.

  3. Question

    Lakshminarayanan K.G.: Entire company. Okay. Okay. So in terms of -- within India. And last year, I think serra was almost like INR131 crores or so. So this year, at this trend rate, what will be in that for serra?

    Answer, mukund kabra

    Mukund Kabra: We will be expecting about INR115 to INR120 Crores for the year.

  4. Question

    Lakshminarayanan K.G.: And the SciTech business, right, I mean, have we seen growth in SciTech? Because I think in FY '24, they're growing pretty healthy there. Yes. So how do you anticipate growth in that part of the India business?

    Answer, mukund kabra

    Mukund Kabra: This year, we expect a good growth to come from the SciTech. Lakshminarayanan K.G.: Okay. And overall, India would grow at what rate this year?

  5. Question

    Lakshminarayanan K.G.: Okay, okay. And how is Europe shaping up? Because we see a decline in the first half I mean, in this quarter. But how do you think about Europe?

    Answer, mukund kabra

    Mukund Kabra: Evoxx revenue is on the lower side in the first half, but we expect that it showed smaller growth in the last year at the end of the year because as we were talking and I think we might have talked last time, probably, we were expecting some of the contracts in the Evoxx, which has been signed. So we expect a positive this year, particularly at the end of the year. The next half will be better from the Evoxx side.

  6. Question

    Lakshminarayanan K.G.: Yes. I mean, I believe we had some approvals in the food side in Europe. And I think not recently, but even several quarters back, you had mentioned that you're getting some approvals and that would actually open up a lot of opportunities in Europe. So on the food part in Europe, Page 10 of 18 Advanced enzymes Advanced Enzyme Technologies Limited ' IVtiL’ful.X/YMllbLilt‘ November 13, 2024 what are we tracking? Is it -- is it the gestation period is longer? Can you just help me understand that?

    Answer, mukund kabra

    Mukund Kabra: Yes, there is a gestation period, which is a little bit longer. At the same time, there are certain issues, some of the issues are coming with the freight and all of those areas, the freight cost is also on a higher side. Some of the other areas are also affecting some credits and some other areas, and we are working on how do we resolve those problems?

  7. Question

    Lakshminarayanan K.G.: Got it. Just one last question related to the rest of the world. And if you look at the rest of the world in animal feed and non-animal feed, where do you see growth? Is the growth coming from animal feed business or the non-animal feed business?

    Answer, mukund kabra

    Mukund Kabra: Animal Feed, like we will be expanding into some other areas, particularly and we are working on those. At this point of time, this year, I don't see much of the growth to come from the animal feed, but we are trying to explore some other areas like the ruminant areas and solutions for aquaculture, and all of those other areas, we are trying to explore at this point of time. Non- animal or non-food bioprocessing area is looking very decent for this year, particularly.

  8. Question

    Lakshminarayanan K.G.: That profitability, when compared to last year, this year, would we end at a better picture than last year in terms of our operating profit or the net profit?

    Answer, beni rauka

    Beni Prasad Rauka: Yes, I think we should look at the kind of numbers we had last year, at least we are likely to outperform once we get a single-digit growth.

  9. Question

    Lakshminarayanan K.G.: Got it. Is there any surprise that actually came in the last few months? Has actually changed...

    Answer, beni rauka

    Beni Prasad Rauka: Some of the sales, as Mukund has mentioned, has not picked up. Like customers, they are taking their own time there. Initially, when as you mentioned in the month of August, where we could see some kind of visibility. But then there are several things which I think customers are also looking at it. And therefore, the Indian sales is not picking up. In the USA, if you really see -- the growth is there and now they are working that most of the nutraceutical customers. So they use our branded formulated product name in their product.

    Answer, beni rauka

    So instead of using any kind of specific ingredient, now we are trying to convince our customers that look, this is our brand name and which we are supplying. So you use on your nutraceutical, the name of our product. So it becomes more, in that sense, customer-centric as well as the kind of brand visibility we create over a period of time. So a couple of such issues are there, which I think are taking some time to shape up.

    Answer, beni rauka

    Beni Prasad Rauka: Sometime, you know, trials are going on like on biocatalysts. And customers also making trials. So getting an order for a big, you can say, commercial order takes time. So initially, you gave it, yes, I think a couple of trials are going successful. Hopefully, now next quarter, we shall be getting the big order. But then customers, they may take their time because they have to also reschedule various -- internally, many processes also. So for that, sometime, it takes time.

    Answer, mukund kabra

    Mukund Kabra: But Nikhil, to answer your question, our business doesn't go with the PO basis. We hardly always have any POs. The number of POs at any given time is not more than 10, 12 Crores. Nikhil: Okay. So sir, just 2 questions here, 2 follow-ups. One is when you say the customer is undergoing trials or validations. In that sense -- and it could be naive to say, but does it mean that the business which we were expecting gets deferred over time?

    Answer, mukund kabra

    Or do you think that the business is lost completely? Because if he is taking some time and validation and that time line has shifted, then probably it will come in FY '26, what we were thinking of growth in this year. Would that be right assumption? Or is it like the project gets scrapped completely?

    Answer, mukund kabra

    Mukund Kabra: No, it's most of the time, this is a novel solutions, what you come out. And basically, it takes time because a lot of times, they need to file the DMF, they need to file many other areas. And there can be multiple possibilities which are not in your hands, how long it can take. You can only always estimate based on the feedback and other areas, but sometimes, it always differ. And this is what the case is. Sometimes we are optimistic. We were a little bit more optimisti c that this should come up as early as possible, but we realize that it will take some more time.

    Answer, mukund kabra

    Nikhil: Okay. And secondly, coming to your near-term guidance on second half, you said for the full year, we should grow at single digit. Even if I adjust for this INR8 crores, it seems we have to grow in second half by at least 15%, 20% on a year-on-year basis to get that number of 6%, 7%. Now considering the lack of visibility, which you also have, how do you build confidence that this kind of growth is achievable in the near term?

    Answer, mukund kabra

    Mukund Kabra: The way I can look at it is basically whatever the numbers I can see is forecast at this point of time, I can see that we are not going to de-grow. We are going to grow. What will be that number, that still we need to really work out, which will be the really realistic numbers. Nikhil: Okay. But you don't have any direct communication from the clients in terms of -- so between the time you get an order and your delivery, what would be the time period generally? Like, is it a 1-month kind of a time period when you have to supply from the day you get the order?

    Answer, mukund kabra

    Mukund Kabra: It differs on product to product. Sometimes it's 6, 7 days, sometimes, like it's a month. Nikhil: Okay. Fine. I'll come back in the queue.

  10. Question

    So the first one was on the Europe business, we see like a very sharp decline. So does that indicate like we've lost any customers or lost market share over there? And even the rest of the world, we see like a sharp decline. Even if we adjust for the deferred revenue, even then just trying to understand that 35% drop.

    Answer, mukund kabra

    Mukund Kabra: I don't see there is any customer loss as of now. Yes, there is a small one, which was like $1 million, which we realized last year, which we are knowing that this year will not be coming up because of some other reasons because the -- they changed the process in other areas. Besides that, there is no customer loss, what we can expect this year in the European business. We expect that this should pick up.

  11. Question

    Shreyans Gathani: Okay. And a second question. So basically, are we like lacking on the product innovation side? So for -- like if I look at Novozymes, Chr. Hansen and other combined entity commentary and their guidance, they just upped their guidance and they are even more positive versus we are like losing sales. We're actually increasing guidance and we are losing. So are we like falling behind on the R&D front compared to them in terms of product, or just trying to understand that?

    Answer, mukund kabra

    Mukund Kabra: If you ask about Novozyme and these people, they are much ahead, no if and but. But that is where we have our own niche areas and other areas. We are really focusing on the R&D area. We are developing our R&D capabilities. We have a plan to increase it by threefold. And this is what our overall focuses are. We will need some more time to really go on and take on the Novozymes and other people in all the different segments.

    Answer, mukund kabra

    At the same time, we are working really hard to go to that level.

  12. Question

    Shreyans Gathani: Got it. So by when do we expect the R&D to pick up to 3x, 4x that you are mentioning?

    Answer, mukund kabra

    Mukund Kabra: We are building up our new R&D center right now in Nasik. This should be fully operational by the end of next year. Then we will have like, slowly, slowly, we'll really ramp up on the R&D front.

  13. Question

    Anuj Gakhar: Okay. And the other one is, I can see that -- looking at the balance sheet that we are constantly going on the reserves part of it. So is there any plan of -- any kind of reward to the shareholders in terms of buyback or bonus in the future?

    Answer, mukund kabra

    Mukund Kabra: Those decisions have to be taken by the Board. Like if you really look at it, we increased the dividend, and we continue to cover dividend policy. That's all what I can say. Probably, buyback is not -- not possible. But Rauka ji can give more clarity on that. Rauka ji?

    Answer, beni rauka

    Beni Prasad Rauka: No, I think buyback is not efficient. Because it is also taxable again in the hands of the recipient. So for shareholders, there will be a cash outflow. So as you rightly mentioned, I think dividend is what every year, we have been increasing. So that is what is the way forward.

  14. Question

    Anuj Gakhar: Sure. So one small last question. I was listening on the news that there might have been some impact to this quarter because of Red Sea related issues in terms of the deliveries along that corridor. Was an impact of the Red Sea concerns?

    Answer, mukund kabra

    Mukund Kabra: The freight cost is on the higher side, Anuj ji. We have, an impact, of about INR1.5 crores in this quarter, particularly because of the freight cost.

  15. Question

    Anuj Gakhar: Okay. So if we account for that, then we'll be around the same margin, that 33%? Page 14 of 18 Advanced enzymes Advanced Enzyme Technologies Limited ' IVtiL’ful.X/YMllbLilt‘ November 13, 2024 Beni Prasad Rauka: Yes, yes, yes.

    Answer, mukund kabra

    Mukund Kabra: No, I think I don't have exact number. We will achieve -- actually, we have more than 150 scientists at this point of time. There may be more. But I don't have an exact number as of now, but should be more than 150 plus. That's what I can say. Your second question is how... Vivek: How much EBITDA margin we can expect for this financial year, sir?

    Answer, beni rauka

    Beni Prasad Rauka: So I mean, once the revenue increases, I think the improvement will definitely be there. So we expect that the EBITDA margin should be in the range of anywhere over 30%. It will be in the range of 30% to 33%.

  16. Question

    Rohit Ohri: Sir, any rough work that you have done or anything that we should anticipate over the next 1, 1.5 or 2 years or something like that?

    Answer, mukund kabra

    Mukund Kabra: No. In next one years, I don't expect any acquisition at least in the US, particularly.

  17. Question

    Rohit Ohri: Okay. Sir, my second question is related to Evoxx. In the previous quarter, you did mention that you were looking for some sales that were supposed to come through from there, somewhere around INR1.4 million, INR1.5 million kind of sales that was supposed to come from there. Has that passed through? Or are there some difficulties over there as well?

    Answer, mukund kabra

    Mukund Kabra: No. What I said was that is fine, that is what we were expecting. We do have a PO of that, which is pan out for a whole year, and that is where we expect that the next half year will be the better for the US. And probably we will have higher sales than the low last year, particularly in the US. Page 16 of 18 Advanced enzymes Advanced Enzyme Technologies Limited ' IVtiL’ful.X/YMllbLilt‘ November 13, 2024 Rohit Ohri: Sir, many of these customers' clients from the international market, they must be trying to make their own budget as the year is coming to an end.

Questions about this call

When was the Advanced Enzyme Technologies Q2 FY25 earnings call transcript filed?
Advanced Enzyme Technologies filed the transcript with the exchange on 19 Nov 2024. This page is built from that transcript.
What does this page list?
33 statements from the transcript across 6 topics, 19 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 27 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Advanced Enzyme Technologies Q2 FY25 concall: Advanced Enzyme Technologies Limited's business does not operate on a PO basis, and the value of POs at any given time is not more than 10, 12 Crores · DalalOS